Home News Page 3

News

Triphase’s TRPH-222 enters Clinical Phase I trials

Triphase Accelerator’s TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma, has been dosed in...

Mersana Presents Updated Data about its Dolasynthen Platform and Synthemer Scaffold

Clinical-stage bio-pharmaceutical company, Mersana Therapeutics, presented preclinical data from the company's proprietary Dolasynthen platform and its modular Synthemer scaffold...

MilliporeSigma Elevates its BioContinuum™ Platform Strategy to Deliver ‘ContiGuous’ Bioprocessing

MilliporeSigma today unveiled its BioContinuum™ Buffer Delivery Platform, a new building block in the BioContinuum™ Platform for next-generation...
Daiichi Sankyo

Daiichi Sankyo Accelerates BLA Submission for [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast...

Earlier this week Daiichi Sankyo announced plans to accelerate filing of their Biologics License Application (BLA) with the U.S....

Pivotal Trial of Enfortumab Vedotin Shows Positive Topline Results in Locally Advanced or Metastatic...

The first cohort of patients in a pivotal phase II single-arm clinical trial, known as EV-201, shows positive topline...

First-in-class Immunotherapeutic Approach Shows Efficacy in Neuroblastoma

Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to...

Rapidly Expanding MabPlex International Secures U.S. $ 59.1 Million Series A Financing

In an announcement made to the international business and financial press, MabPlex International, a global Contract Development and Manufacturing...

U.S. Food and Drug Administration Rejects Sacituzumab Govitecan

The U.S. Food and Drug Administration (FDA) has rejected sacituzumab govitecan also known as IMMU-132, a novel, investigational, antibody-drug...
MabPlex

MabPlex’s Manufactured Monoclonal Antibody Receives IND Approval from the U.S. Food and Drug Administration

Leading Contract Development and Manufacturing Organization (CDMO) MabPlex International, serving the global biopharmaceutical and biotechnology industries with sites in...

First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate Targeting AXL in...

The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing...

FEATURED